Original title: Aoxiang Pharmaceutical invested 35 million yuan to participate in the investment and exploration of high-quality enterprises in the pharmaceutical field
A few days ago, Aoxiang Pharmaceutical announced that it has signed the “Shanghai Yikang Phase II Equity” with various partners. Investment Partnership (Limited Partnership) Partnership Agreement. According to the agreement, Aoxiang Pharmaceutical will subscribe for a capital contribution of 35 million yuan as a limited partner, accounting for 11.6667% of the total subscribed capital of 300 million yuan for Shanghai Yikang Phase II Equity Investment Partnership (Limited Partnership).
The announcement shows that no less than 90% of the fund’s actual capital contribution that can be used for investment will be used to invest in high-quality unlisted companies in the medical field in China and abroad, aiming to explore high-quality assets in the pharmaceutical industry in the future. Discover outstanding companies with cutting-edge technologies in the fields of biotechnology, medical devices and innovative drugs.